Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining interferon beta response status in multiple sclerosis patients.

Richard A Rudick1, Jar-Chi Lee, Jack Simon

  • 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA. rudick@cdf.org

Annals of Neurology
|September 25, 2004
PubMed
Summary

Identifying interferon-beta (IFN-beta) responsiveness in multiple sclerosis (MS) is crucial. New MRI lesions during treatment indicate a poorer response to IFN-beta therapy, suggesting MRI may guide treatment decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional anaesthesia and chronic postsurgical pain: a systematic review and network meta-analysis.

British journal of anaesthesia·2026
Same author

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

The Lancet. Oncology·2026
Same author

Impact of a Routine Third Trimester Ultrasound Policy on Obstetric, Neonatal and Service Delivery Outcomes in an Australian Tertiary Centre.

The Australian & New Zealand journal of obstetrics & gynaecology·2026
Same author

Beyond the 2024 McDonald criteria for defining and diagnosing multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

How Health Departments Can Use Inside-Outside Strategies to Build Partnerships With Community Power-Building Organizations to Achieve Structural Change.

The Milbank quarterly·2026
Same author

Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Therapeutic Drug Monitoring

Background:

  • Interferon-beta (IFN-beta) is a common treatment for multiple sclerosis (MS), reducing relapses and MRI lesions.
  • Individual patient responses to IFN-beta vary, but validated methods to predict responsiveness are lacking.
  • Accurate classification of IFN-beta responders is essential for optimizing treatment strategies.

Purpose of the Study:

  • To evaluate methods for classifying IFN-beta responder status in MS patients.
  • To assess the utility of relapses and MRI lesions in defining treatment response.
  • To determine if MRI activity predicts long-term disease progression.

Main Methods:

  • Analysis of data from 172 patients in a 2-year placebo-controlled clinical trial of IFN-beta1a.

Related Experiment Videos

  • Classification of patients as responders or nonresponders based on relapse counts and MRI lesion burden (T2 and gadolinium-enhancing).
  • Assessment of outcomes including Expanded Disability Status Scale, Multiple Sclerosis Functional Composite, and brain parenchymal fraction changes.

    • Main Results:

    • High relapse rates correlated with disease progression, with similar trends in both IFN-beta1a and placebo groups.
    • High numbers of new MRI lesions during treatment were associated with significantly greater disease progression exclusively in the IFN-beta1a arm.
    • Baseline patient characteristics did not predict differential outcomes.
    • New MRI lesion activity during IFN-beta1a treatment correlates with poor response.

    Conclusions:

    • MRI lesion activity during IFN-beta1a treatment is a key indicator of therapeutic response.
    • MRI-based classification holds potential for guiding therapeutic decisions in MS.
    • This approach can improve clinical trial design and biomarker research for IFN-beta therapy.